VistaGen Therapeutics (VTGN) AI Stock Analysis

• Market Cap: $72.02M
• Dividend Yield: N/A
• Average Volume (3M): 259.48K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.83
• Revenue Growth: -33.00%
• EPS Growth: 54.91%
• Country: US
• Employees: 48
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.43
• Shares Outstanding: 29,157,734
• 10 Day Avg. Volume: 397,212
• 30 Day Avg. Volume: 259,478
• PEG Ratio: -0.06
• Price to Book (P/B): 1.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.61
• Enterprise Value/Market Cap: >-0.01
• Enterprise Value/Revenue: >-0.01
• Enterprise Value/Gross Profit: -0.05
• Enterprise Value/Ebitda: <0.01
• 1Y Price Target: $12.00
• Price Target Upside: 372.44% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 50 Neutral
• Price Target: $2.50 ▼(-1.57%Downside)

VistaGen's stock score reflects a challenging financial landscape with persistent losses and negative cash flow, offset by strategic advancements and a solid equity base. The technical analysis suggests cautious optimism, while recent corporate events and earnings call updates provide a positive outlook albeit with significant risks.

Positive Factors

Clinical Trials

Vistagen's PALISADE-3 and PALISADE-4 studies for fasedienol in social anxiety disorder are progressing as expected, potentially confirming positive results from previous trials.

Regulatory Progress

Vistagen is making strides on the regulatory front with an IND opened for itruvone for major depressive disorder.

Negative Factors

Financial Performance

VistaGen reported a net loss of $14.1 million in their F3Q25 results.

Project Delays

The timeline for Vistagen's PALISADE-4 study has been delayed, although not due to patient demand.

VistaGen Therapeutics Business Overview & Revenue Model

Company Description

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

How the Company Makes Money

VistaGen Therapeutics primarily generates revenue through the development and commercial licensing of its CNS disorder therapies. The company earns money by advancing its product candidates through clinical trials and securing partnerships or licensing agreements with larger pharmaceutical companies. These partnerships may include milestone payments and royalties based on sales of successfully commercialized products. VistaGen may also receive research and development funding from collaborations aimed at co-developing or enhancing its therapeutic offerings. Additionally, strategic collaborations and partnerships play a crucial role in enhancing the company's research capabilities and expanding its reach in the pharmaceutical market.

VistaGen Therapeutics Financial Statement Overview

Summary

VistaGen Therapeutics faces significant challenges with consistent losses and negative cash flow. Despite a strong equity position and manageable debt levels, profitability and operational efficiency need improvement for long-term success.

Income Statement

The company's revenue growth has been volatile, with a significant drop this year compared to the previous year. Gross profit margin remains stable due to the low cost structure, but the net profit margin is severely negative. The EBIT and EBITDA margins are also deeply negative, indicating operational inefficiency. Despite these challenges, there is a slight increase in revenue compared to the previous year, showing potential for future growth.

Balance Sheet

VistaGen Therapeutics has a relatively low debt-to-equity ratio, indicating a conservative capital structure. However, the return on equity is negative, impacted by consistent net losses. The equity ratio is strong, suggesting financial stability and a solid foundation for future growth. Despite these strengths, the company needs to improve profitability to leverage its equity effectively.

Cash Flow

The company's free cash flow is negative but shows improvement from the previous year, suggesting progress towards better cash management. Operating cash flow remains negative, but the ratio to net income indicates that cash losses are less severe than income losses. Continued focus on reducing cash burn is crucial for future financial health.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	486.00K	1.06M	-227.00K	1.11M	1.09M
Gross Profit	486.00K	1.06M	-227.00K	1.11M	1.09M
EBITDA	-55.34M	-32.45M	-58.74M	-47.05M	-17.44M
Net Income	-51.42M	-29.36M	-59.25M	-47.76M	-17.93M
Balance Sheet
Total Assets	84.34M	123.65M	21.09M	74.64M	108.28M
Cash, Cash Equivalents and Short-Term Investments	80.48M	119.17M	16.64M	68.14M	103.11M
Total Debt	1.51M	2.12M	2.72M	3.04M	3.72M
Total Liabilities	13.95M	9.37M	9.01M	9.93M	16.30M
Stockholders Equity	70.39M	114.29M	12.08M	64.72M	91.98M
Cash Flow
Free Cash Flow	-42.29M	-25.87M	-49.93M	-45.46M	-12.35M
Operating Cash Flow	-42.10M	-25.81M	-49.72M	-45.26M	-12.07M
Investing Cash Flow	-13.15M	-61.00K	-740.30K	-200.40K	-275.40K
Financing Cash Flow	3.21M	128.40M	-1.04M	10.48M	114.10M

VistaGen Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.54
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTGN, the sentiment is Positive. The current price of 2.54 is above the 20-day moving average (MA) of 2.19, above the 50-day MA of 2.30, and below the 200-day MA of 2.62, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 61.35 is Neutral, neither overbought nor oversold. The STOCH value of 67.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VTGN.

VistaGen Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.47B	-0.04	-63.86%	2.34%	16.17%	0.25%
VTGN	50 Neutral	$72.02M	―	-46.28%	―	-33.00%	54.91%
SAVA	43 Neutral	$100.00M	―	-70.59%	―	―	81.00%
VTVT	38 Underperform	$54.28M	―	-130.16%	―	―	65.54%
CLSD	38 Underperform	$64.30M	―	91.63%	―	-55.47%	24.92%
INZY	37 Underperform	$258.25M	―	-141.69%	―	―	-17.06%
JSPR	35 Underperform	$49.72M	―	-101.34%	―	―	21.40%

VistaGen Therapeutics Corporate Events

Vistagen Appoints Elissa Cote as Chief Development Officer

On June 25, 2025, Vistagen Therapeutics announced the appointment of Elissa Cote as Chief Corporate Development Officer, effective June 23, 2025. Ms. Cote, with nearly 30 years of experience in biopharmaceuticals, will lead strategic opportunities to advance Vistagen’s pherine platform and cultivate partnerships. Her appointment is seen as pivotal for Vistagen’s growth, as she brings expertise in business development and strategic transactions, which are crucial for the company’s future commercial launches and partnerships.

The most recent analyst rating on (VTGN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on VistaGen Therapeutics stock, see the VTGN Stock Forecast page.

VistaGen Files Prospectus to Raise $175 Million

On June 17, 2025, Vistagen announced a prospectus supplement filed with the SEC to offer and sell shares of its common stock, aiming to raise up to $175 million. The company also reported its fiscal year 2025 financial results, highlighting significant progress in its clinical-stage pipeline, including the PALISADE program for fasedienol in social anxiety disorder. Vistagen’s ongoing trials and development efforts, such as the PALISADE-3 and PALISADE-4 trials, aim to address unmet needs in mental health and women’s health, with potential implications for future FDA submissions and market positioning.

The most recent analyst rating on (VTGN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on VistaGen Therapeutics stock, see the VTGN Stock Forecast page.

VistaGen Announces Progress on PALISADE-3 Clinical Trial

On June 2, 2025, Vistagen Therapeutics announced that its PALISADE-3 Phase 3 clinical trial for fasedienol, aimed at treating social anxiety disorder, is on track for topline data release in the fourth quarter of 2025. The PALISADE-4 trial is expected to yield results in the first half of 2026. These trials are part of Vistagen’s efforts to establish fasedienol’s effectiveness for a potential New Drug Application submission to the U.S. FDA. The trials incorporate strategic enhancements to replicate the success of the PALISADE-2 trial, which reported positive results in 2023.

The most recent analyst rating on (VTGN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on VistaGen Therapeutics stock, see the VTGN Stock Forecast page.